Erythromycin increases plasma concentrations of ?-dihydroergocryptine in humans

Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies

1992 • 1,134 citations

Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

2000 • 877 citations

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

1999 • 457 citations

Macrolide Antibacterials

1995 • 206 citations

P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans

2000 • 144 citations

Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen.

1997 • 72 citations

Dopamine receptor profile of co-dergocrine (Hydergine ®) and its components

1982 • 38 citations

Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine

1990 • 37 citations

Bromocriptine Modulates P-Glycoprotein Function

1998 • 33 citations

Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double-blind, placebo-controlled study

2000 • 32 citations

Alpha-dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study

2009 • 19 citations

Bioequivalence study of alpha-dihydroergocryptine: utility of metabolite evaluation.

1996 • 12 citations

[Ergotism in a psychiatric setting caused by combined dihydroergotamine-erythromycin propionate. Apropos of a case].

1980 • 11 citations

Highly sensitive and specific radioimmunoassays for dihydroergotoxine components in plasma

1984 • 8 citations

Plasma and urine pharmacokinetics of the dopamine agonist a-dihydroergocryptine in patients with hepatic dysfunction

2001 • 4 citations